Ultragenyx Pharma (RARE) Tops Q4 EPS by 10c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.89), $0.10 better than the analyst estimate of ($1.99).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) PT Lowered to $25 at H.C. Wainwright
• ICICI Securities Starts Jain Resource Recycling (JAINREC:IN) at Buy (1)
• Barclays Downgrades Ipsen SA (IPN:FP) (IPSEF) to Underweight